Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03822065 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Food Effect Study of LY03005
A Phase 1 study of Major Depressive Disorder, sponsored by Luye Pharma Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT03822065 is a Phase 1 study of Major Depressive Disorder that has completed, run by Luye Pharma Group. The registered enrollment target is 34 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03822065, a Phase 1 study of Major Depressive Disorder, has completed, sponsored by Luye Pharma Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective if this study is to assess the relative bio-availability of single oral doses of 80 mg LY03005 tablets administered to healthy subjects under fed versus fasted conditions in a 2-period, crossover trial.
Conditions Studied
Interventions
- DRUG LY03005
Study Locations (1)
Maryland
- Pharmaron CPC, Inc. - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2019-01-16 |
| Est. Completion | 2019-02-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03822065
The ClinicalTrials.gov registry entry for NCT03822065 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (91% lower). The listed sponsor is Luye Pharma Group, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which LY03005 is the first listed.
NCT03822065 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT03822065 about?
NCT03822065 is a clinical study titled "A Relative Bioavailability Food Effect Study of LY03005". The objective if this study is to assess the relative bio-availability of single oral doses of 80 mg LY03005 tablets administered to healthy subjects under fed versus fasted conditions in a 2-period, crossover trial.
What is the current status of trial NCT03822065?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2019-01-16. Estimated completion is 2019-02-16.
What conditions does trial NCT03822065 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT03822065?
The interventions under investigation include: LY03005 (DRUG).
Who is sponsoring clinical trial NCT03822065?
This trial is sponsored by Luye Pharma Group, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03822065 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neural Response to Inflammatory Challenge in Major Depressive Disorder
RECRUITING · Phase 1
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
RECRUITING · Phase 1
-
A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression
RECRUITING · Phase 1
-
Antiviral Treatment OF Cytomegalovirus IN Depression
RECRUITING · Phase 1
-
Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.